Our result was consistent with the findings of Baghy et al., in which the idea that decorin acts as a secreted tumor repressor during hepatocarcinogenesis by hindering the action of another receptor tyrosine kinase, such as the PDGFRα, was supported and DCN was suggested be a novel therapeutic agent in the battle against liver cancer [41]. The gene discussed is DCN; the disease is liver cancer.